Facioscapulohumeral Muscular Dystrophy 2 / "FSHD4 Digenic" — Comprehensive Research Report

Note on nomenclature: The disease name "Facioscapulohumeral Muscular Dystrophy 4 Digenic" does not correspond to an established OMIM/GeneReviews entity. The clinical and molecular literature — and OMIM's own entry — designates the digenic form of FSHD as FSHD2 (OMIM #158901, "FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2, DIGENIC; FSHD2"), distinct from the classical, D4Z4-contraction-driven FSHD1 (OMIM #158900). MONDO's disease-hierarchy term for the digenic entity is the FSHD2 node; if MONDO:0030355 resolves to a differently-numbered label in the KB's local MONDO snapshot, that is very likely this same FSHD2/digenic concept under a different display number, and should be confirmed by direct MONDO lookup before curation — I did not verify MONDO:0030355 against a live MONDO release in this pass and flag this as unverified. Everything below is written against FSHD2 (digenic FSHD) as the target entity, since every primary source I found in this literature search uses that identity. (Source: OMIM #158901)

1. Disease Information

FSHD2 is one of the two principal molecular subtypes of facioscapulohumeral muscular dystrophy (FSHD), a progressive skeletal myopathy classically presenting with asymmetric weakness of facial, scapular stabilizer, and humeral (upper-arm) muscles. Both FSHD1 and FSHD2 converge on the same final mechanistic lesion — somatic derepression of the transcription factor DUX4 encoded within the D4Z4 macrosatellite repeat array on chromosome 4q35 — but reach it by different genetic routes. In FSHD1 (~95% of cases), a contracted D4Z4 array (1–10 repeat units, vs. 11–100+ in the general population) on a permissive 4qA haplotype causes chromatin relaxation in cis. In FSHD2 (~5% of clinically diagnosed FSHD, but a higher share — up to ~16% — among "phenotypic FSHD without D4Z4 contraction" cohorts), the D4Z4 array is of normal length on both chromosome-4 alleles; instead, a heterozygous loss-of-function variant in a trans-acting chromatin modifier — most often SMCHD1 (18p11.32), occasionally DNMT3B (20q11.21), rarely LRIF1 (1p13.3, biallelic) — causes D4Z4 chromatin relaxation genome-wide (including at chromosome 4 and chromosome 10 D4Z4 arrays), which becomes pathogenic only in the presence of an independently-inherited permissive 4qA(159/161/168) D4Z4 haplotype on chromosome 4. This two-locus requirement is why FSHD2 is described as digenic. (Sources: NORD; OMIM #158901; Lemmers et al., Nat Genet 2012, PMID:23143600)

Key identifiers: - OMIM: #158901 (FSHD2, digenic) — distinct from #158900 (FSHD1) - Genes: SMCHD1 (HGNC:29090, chr18p11.32), DNMT3B (HGNC:2979, chr20q11.21), LRIF1 (HGNC:29225, chr1p13.3) - GeneReviews: "Facioscapulohumeral Muscular Dystrophy" (NBK1443) covers both FSHD1 and FSHD2 - Orphanet: FSHD is ORPHA:269 (parent); FSHD2 has its own Orphanet entry - Synonyms: FSHD type 2; digenic FSHD; SMCHD1-related FSHD; Landouzy-Dejerine dystrophy (historical, applies to FSHD broadly)

Almost all published data derive from aggregated case series, national/regional patient registries (notably the Dutch FSHD registry, NMD 2023), and molecular-diagnostic cohorts rather than individual EHR mining — this is a rare, molecularly-defined disease studied primarily through specialist neuromuscular centers.

2. Etiology

Disease Causal Factors

FSHD2 is purely genetic/epigenetic in origin — a digenic trans/cis combination: 1. A heterozygous pathogenic variant in a D4Z4 chromatin-repressor gene (SMCHD1 most commonly; DNMT3B or LRIF1 rarely), and 2. A permissive 4qA D4Z4 haplotype (4qA-161, 4qA-159, 4qA-168) on at least one chromosome 4 allele, inherited independently and segregating separately in families.

Neither factor alone causes disease: a chromatin-modifier mutation without a permissive 4qA haplotype produces D4Z4 hypomethylation without symptomatic FSHD, and a permissive haplotype without a chromatin-modifier mutation is simply the common population allele. (Source: Lemmers et al. 2012, PMID:23143600; FSHD Society genetics page)

Genetic Risk Factors

• SMCHD1 loss-of-function variants: missense, nonsense, frameshift, and splice-site variants distributed across the entire coding sequence (18 exons); reduce SMCHD1 protein function/dosage. (PMID:25370034; PMID:31879416)
• DNMT3B heterozygous variants: a minority of SMCHD1-negative FSHD2 cases (van den Boogaard et al., AJHG 2016).
• LRIF1 biallelic (homozygous or compound-heterozygous) loss-of-function variants: rare, reported in FSHD2 patients negative for SMCHD1/DNMT3B; notably recessive, unlike the dominant SMCHD1/DNMT3B mechanism. (PMID:32467356)
• Double SMCHD1 variants in a single patient — a synergistic "two-hit" combination that deepens D4Z4 hypomethylation and increases penetrance/severity beyond either variant alone. (Sacconi et al., EJHG)
• The permissive 4qA haplotype itself is the second obligate risk allele, common in the general population but necessary (not sufficient) for disease.
• SMCHD1 as a modifier of FSHD1 severity: even in classic FSHD1 (D4Z4-contracted), a co-inherited SMCHD1 hypomorphic variant increases severity ("FSHD1+2" digenic-modifier state), while FSHD1-permissive-allele carriers without an SMCHD1 variant are only mildly affected. (PMID:24075187; "FSHD1 and FSHD2 form a disease continuum," Neurology 2019)

Environmental/Non-Genetic Risk Factors

No environmental, toxin, infectious, or lifestyle causal risk factors are established for FSHD2 — it is a monogenic-plus-modifier epigenetic disease. No gene-environment interaction data were found in this search.

Protective Factors

• Non-permissive 4qB haplotype on the second chromosome-4 allele, or absence of any permissive 4qA allele, is protective even in an SMCHD1-variant carrier, because the DUX4 transcript lacks the stabilizing polyadenylation signal (PAS) needed to produce toxic protein. (PMC10951985)
• Milder/non-pathogenic SMCHD1 hypomorphic alleles and residual methylation near control levels are associated with incomplete penetrance: in one cohort, of 26 individuals with D4Z4 hypomethylation + SMCHD1 mutation + permissive haplotype, 5 (19%) were clinically asymptomatic, and their proximal-D4Z4 methylation more closely resembled unaffected controls. (PMID:25370034; "Differential DNA methylation ... asymptomatic carriers," Neurology)

3. Phenotypes

FSHD2's clinical phenotype is indistinguishable from FSHD1 at the bedside; molecular testing is required to separate them. Suggested HPO terms are given per phenotype.

(Sources: EyeWiki — Ophthalmologic Manifestations of FSHD; Padberg 1995 Muscle & Nerve; PMC5898965; Medscape FSHD overview; Journal of Neurology respiratory follow-up, 2022)

Age of onset / severity / progression: Onset is highly variable — classically second decade but ranging from infancy ("infantile FSHD," most severe, disproportionately linked to very large D4Z4 contractions but also seen with severe SMCHD1/DNMT3B combinations) to late adulthood. Progression is typically slow (~1–4%/year strength decline) and asymmetric, but FSHD2 as a group has been reported as on average milder in isolation than FSHD1, while the "FSHD1+2" digenic-modifier combination is substantially more severe than D4Z4 copy number alone would predict. (PMID:24075187)

Quality of life: No FSHD2-specific EQ-5D/SF-36 dataset was located in this pass; QoL burden in FSHD generally is driven by shoulder-girdle disability, fatigue, and pain, per the Dutch registry's longitudinal PROs. (NMD 2023)

4. Genetic/Molecular Information

Causal Genes

Variant classification/type

SMCHD1 variants reported in FSHD2 are missense, nonsense, frameshift, and canonical/near-splice-site variants scattered across all 18 exons, generally interpreted as loss-of-function/haploinsufficiency (ACMG/AMP framework via ClinVar/ClinGen). This contrasts with the gain-of-function missense variants clustered in the GHKL-ATPase domain (exons 3–13) that instead cause Bosma arhinia microphthalmia syndrome (BAMS) — a distinct, non-overlapping SMCHD1-related phenotype with no muscular dystrophy features (see §14/genotype note below). (PMID:28067909; Nat Genet 2017, PMC6016475; Neurology — FSHD2 and BAMS)

A 2025 review specifically addresses the practical difficulty of interpreting SMCHD1 variants: "SMCHD1 genetic variants in type 2 facioscapulohumeral dystrophy and challenges in predicting pathogenicity and disease penetrance" (PMC12185756) — underscoring that many SMCHD1 variants remain VUS without functional (methylation) data.

Allele frequency / population data

No FSHD2-specific gnomAD/ExAC carrier-frequency figures were located; SMCHD1 loss-of-function variants are individually rare/private, consistent with a dominant disease-causing gene under purifying selection, but rare benign/hypomorphic SMCHD1 variation exists in the general population and complicates VUS interpretation.

Somatic vs. germline

FSHD2-causing SMCHD1/DNMT3B/LRIF1 variants are germline. (No somatic-mosaic FSHD2 case was identified in this search, though germline mosaicism for the permissive 4qA haplotype and for D4Z4 contractions is well documented in FSHD1 generally.)

Functional consequences / mechanism at the molecular level

• SMCHD1 loss-of-function → reduced D4Z4 CpG methylation at the DR1 region on both chromosome 4 and chromosome 10 D4Z4 arrays (a systemic, trans-acting epigenetic defect, unlike FSHD1's cis, chromosome-4-only lesion).
• Methylation quantification (Southern blot, methylation-sensitive restriction digestion of the DR1 region): controls ~45–50%; FSHD2 average ~11%, with values dropping below a diagnostic threshold of ~25% (recent guideline work refines this to distinct thresholds by 4qA/4qA vs. 4qA/4qB genotype, below 40% in SMCHD1-variant carriers on the DR1 assay). (Giardina et al. 2024 best-practice guidelines, PMID:38685133; Clinical Epigenetics 2024)
• Hypomethylation + chromatin relaxation on a permissive 4qA haplotype permits low-level, sporadic transcription of the DUX4 retrogene encoded in the most distal D4Z4 repeat unit.
• The permissive haplotype supplies pLAM, a sequence immediately distal to the repeat that furnishes a stable polyadenylation signal (PAS) for the DUX4 transcript — without it (non-permissive 4qB), DUX4 mRNA is unstable and non-pathogenic even with full chromatin relaxation. (PMC10951985)

Epigenetic information

FSHD2 is fundamentally an epigenetic disease: the causal lesion at the DUX4 locus is a methylation/chromatin defect, not a coding mutation at the effector locus itself. SMCHD1 and LRIF1 physically converge at the D4Z4 repeat and at the LRIF1 promoter but act through different molecular mechanisms to enforce silencing (Commun Biol 2023, PMC10307901). A 2024 study showed engineered FSHD mutations trigger D4Z4 heterochromatin disruption and a feedforward DUX4 network activation loop (PMC10951985).

Modifier genes

• SMCHD1 itself modifies FSHD1 severity when co-inherited with a D4Z4 contraction.
• Double SMCHD1 variants act synergistically to deepen hypomethylation/penetrance.
• Common D4Z4 repeat-length variants and CNV/SNP background at 4q35 modulate penetrance; a 2018 study characterized a common D4Z4 variant conferring biallelic DUX4 expression as a penetrance modifier in FSHD2 (PMID:29162933).

Chromosomal abnormalities

Not a feature of FSHD2 — the disease-defining D4Z4 array is normal-length; no aneuploidy/translocation mechanism is described.

5. Environmental Information

No specific environmental, occupational, toxin, or infectious contributing factors, and no infectious triggers, were identified for FSHD2 in this literature search — consistent with its purely genetic/epigenetic digenic etiology. Lifestyle factors (exercise) are relevant to management (see §12) rather than etiology.

6. Mechanism / Pathophysiology

Causal chain (numbered, FSHD2-specific)

1. A heterozygous loss-of-function variant in SMCHD1 (or, less often, DNMT3B; rarely biallelic LRIF1) reduces the dosage/activity of a chromatin-repressive complex that normally maintains CpG hypermethylation and heterochromatic compaction of the D4Z4 macrosatellite repeat.
2. This leads to genome-wide D4Z4 hypomethylation, affecting D4Z4 arrays on both chromosome 4 and chromosome 10 (in contrast to FSHD1's chromosome-4-restricted, cis-acting contraction) — average methylation falls from ~45–50% (control) to ~11% (FSHD2), often below a ~25% diagnostic threshold.
3. Chromatin relaxation at the distal D4Z4 unit results in low-level, sporadic somatic transcription of the DUX4 retrogene, which is otherwise silenced in adult somatic tissue outside the germline/early cleavage-stage embryo.
4. If and only if the individual also carries, on the same chromosome-4 allele, a permissive 4qA haplotype bearing the pLAM sequence — this provides a stable polyadenylation signal, so DUX4 mRNA escapes degradation and is translated into functional DUX4 protein (this is the point at which the second, independently-segregating genetic hit becomes obligatory; without it the pathway is inferentially blocked and the individual remains a hypomethylated-but-unaffected carrier).
5. DUX4 protein — a double-homeodomain transcription factor normally restricted to early cleavage-stage/germline expression — activates an ectopic transcriptional program in differentiated skeletal-muscle nuclei, inducing normally-silent germline/cleavage-stage genes (e.g., ZSCAN4, LEUTX, MBD3L2, TRIM43, PRAMEF1 and related PRAMEF-family genes). (Search summary of DUX4-target literature; patent/target compilations e.g. USPTO 10342786)
6. This ectopic gene-activation program triggers (a) oxidative-stress and DNA-damage responses, (b) innate-immune/inflammatory gene activation, and (c) pro-apoptotic signaling, and feeds forward to further destabilize D4Z4 heterochromatin ("feedforward DUX4 network activation," PMC10951985).
7. Sustained, stochastic DUX4-driven cytotoxicity in a small fraction of myonuclei (DUX4 protein is detectable in <0.1% of myonuclei at any time, but is thought to be sufficient over years) leads to progressive myofiber atrophy, death, and replacement/fatty-fibrous infiltration, clinically manifesting as the asymmetric facial-scapular-humeral weakness described in §3.
8. Independently, DUX4 dysregulation is inferred (though less mechanistically established) to underlie the extramuscular manifestations — retinal vasculopathy and sensorineural hearing loss — via presumed effects in non-muscle tissue expressing low levels of the permissive-haplotype DUX4 program; this link is inferred from co-segregation with the same genetic lesion rather than demonstrated by direct tissue-level mechanistic study in the sources reviewed here.

Molecular pathways

No single canonical signaling pathway (Wnt/MAPK/mTOR) is the primary FSHD2 lesion; rather, DUX4 acts as a pioneer/master transcription factor reprogramming chromatin accessibility toward a germline-like state. The p38α/β MAPK pathway has been specifically implicated as a druggable node controlling DUX4 expression levels (rationale for losmapimod, §12). Suggested GO term: GO:0043565 (sequence-specific DNA binding, for DUX4) and GO:0006306 (DNA methylation, for SMCHD1/DNMT3B).

Cellular processes

• Apoptosis / programmed cell death (GO:0006915) of DUX4-expressing myonuclei
• Oxidative stress response (GO:0006979)
• Chromatin silencing / heterochromatin formation (GO:0006342)
• Innate immune activation in muscle (chronic low-grade inflammatory infiltrate is a recognized histopathologic feature of FSHD muscle biopsy)

Protein dysfunction

SMCHD1 is a non-canonical SMC (structural maintenance of chromosomes) family protein with: - An N-terminal GHKL-type ATPase domain (unlike the ABC-type ATPase of canonical SMC proteins) - A C-terminal SMC hinge domain that, unusually, mediates homodimerization (not heterodimerization as in cohesin/condensin) via an intermolecular coiled-coil, and binds DNA/RNA directly - A ubiquitin-like domain stabilizing the N-terminal ATPase module (Commun Biol 2019, PMC8286825) - SMCHD1 compacts chromatin at the D4Z4 array and, more broadly, at facultative heterochromatin including the inactive X chromosome and imprinted loci; ATPase activity is required for its association with Xi and, by extension, for its D4Z4-silencing function (Science Signaling 2020; PNAS 2015) - LOF variants → haploinsufficient loss of this compaction activity → D4Z4 relaxation (FSHD2 mechanism) - GOF missense variants clustered in the ATPase domain → BAMS, a craniofacial malformation syndrome with no myopathic phenotype, demonstrating that the same gene produces mechanistically opposite (LOF vs. GOF) diseases depending on variant location/effect (PMID:28067909)

Suggested GO Cellular Component: GO:0000792 (heterochromatin); GO:0005654 (nucleoplasm). Suggested Cell Ontology: CL:0000188 (skeletal muscle cell) as the primary affected cell type; CL:0000646 (basal cell — N/A); myoblast (CL:0000056) is the cell type used in most in vitro DUX4-toxicity models.

Molecular profiling

DUX4-target-gene RNA-seq signatures (ZSCAN4, LEUTX, TRIM43, MBD3L2, PRAMEF-family) are used as pharmacodynamic biomarkers in current clinical trials (Avidity's AOC 1020 program explicitly reports >50% reduction in DUX4-regulated gene expression as a trial endpoint — see §12). (Avidity RNA-seq poster)

7. Anatomical Structures Affected

Organ/system level: Primarily the musculoskeletal system — face (orbicularis oculi/oris), scapular stabilizers (serratus anterior, trapezius, rhomboids), humeral muscles (biceps, triceps; deltoid relatively spared early), abdominal wall, pelvic girdle, and distal lower leg (tibialis anterior). Secondary/extraskeletal: the eye (retinal vasculature — Coats-like retinopathy) and the inner ear/cochlea (sensorineural hearing loss); in severe infantile-onset disease, the CNS (cognitive impairment, epilepsy). Respiratory system secondarily via diaphragm/paraspinal weakness in advanced disease.

Suggested UBERON terms: UBERON:0001630 (skeletal muscle tissue), UBERON:0009471 (orbicularis oculi), UBERON:0003688 (scapular muscle — approximate), UBERON:0001519 (retina), UBERON:0001846 (cochlea), UBERON:0002048 (lung), UBERON:0001103 (diaphragm).

Laterality: Characteristically asymmetric — a clinically distinguishing feature from most other muscular dystrophies, though the mechanistic basis of the asymmetry (stochastic DUX4 derepression per fiber/region) remains incompletely explained.

Cell types (Cell Ontology): CL:0000188 (skeletal muscle fiber/cell), CL:0000056 (myoblast, used in vitro), and by inference vascular endothelial cells of the retina (CL:0000115) for the retinopathy.

8. Temporal Development

Onset: Highly variable, spanning infantile through late-adult onset; classic literature describes second-decade median onset, but FSHD2 cohorts specifically have not been reported in this search as differing systematically in onset age from FSHD1 — severity (not necessarily age of onset) is the axis most studied.

Progression: Slow, chronic, and typically progressive though with periods of apparent plateau; muscle strength declines at an estimated ~1–4%/year. Sequence is classically facial → scapular → humeral → (later) trunk/abdominal → pelvic girdle → distal leg, though order and extent vary widely, including some patients who never progress beyond facial/scapular involvement.

Disease course pattern: Progressive, non-relapsing-remitting; no spontaneous remission is described. Disease duration is lifelong; life expectancy is generally not shortened in most patients (Medscape/PMC5898965 summary above), though morbidity accumulates.

Critical periods / severity determinants: Infantile-onset disease (regardless of FSHD1/FSHD2 molecular subtype) is associated with the most severe, rapidly progressive course and the highest risk of extramuscular involvement (retinopathy, hearing loss, cognitive/seizure phenotype).

9. Inheritance and Population

Epidemiology (FSHD overall, both subtypes combined): - Classic prevalence estimate: ~1:20,000 (5/100,000) - Contemporary Dutch population-based capture-recapture study: prevalence 12/100,000 (≈1 in 8,333) — roughly double the classically cited rate, with an incidence of 0.3/100,000 person-years (~52 newly diagnosed per year in the Netherlands, ~2,000 total affected). This makes FSHD "one of the most prevalent neuromuscular disorders," and the authors note the true prevalence is likely still underestimated due to underdiagnosis. (Deenen et al., Neurology 2014, PMID:25122204; FSHD Society summary) - FSHD2 specifically accounts for ~5% of clinically diagnosed FSHD cases overall, but SMCHD1 variants are found in up to ~16.4% of patients who are phenotypically FSHD but lack a D4Z4 contraction (i.e., a higher fraction of the "FSHD1-negative" diagnostic subgroup than the historical "5%" figure implies).

Inheritance pattern: Digenic, requiring co-inheritance of (1) an autosomal dominant SMCHD1/DNMT3B loss-of-function variant (or, rarely, biallelic recessive LRIF1) and (2) an independently-segregating permissive 4qA D4Z4 haplotype. Because these are unlinked loci (chromosome 18 or 20 vs. chromosome 4), Mendelian segregation of the two factors in families can appear non-classical if only one locus is tested.

Penetrance: Incomplete — ~19% of individuals meeting the full molecular criteria (hypomethylation + SMCHD1 variant + permissive haplotype) are asymptomatic carriers in at least one published cohort (PMID:25370034). Penetrance appears to track quantitatively with degree of D4Z4 hypomethylation.

Expressivity: Markedly variable, even within families carrying the identical SMCHD1 variant and permissive haplotype — attributed to residual methylation, D4Z4 repeat-length background, and biallelic DUX4-expression modifiers.

Genetic anticipation: Not established for FSHD2 specifically in this search (unlike FSHD1, where progressively shorter D4Z4 repeats can occur across generations via further contraction; this mechanism does not directly apply to FSHD2 since the array is not contracted).

Germline mosaicism: Well documented for FSHD1 D4Z4 contractions generally; no FSHD2-specific (SMCHD1) germline mosaicism data were located in this search.

Founder effects / consanguinity: The rare biallelic LRIF1 form is consistent with a recessive mechanism plausibly enriched by consanguinity, though the single reported family in this search was not explicitly described as consanguineous.

Sex ratio / demographics: No FSHD2-specific male:female ratio was located in this search (flagging as a gap; general FSHD literature does not report strong sex skewing, though some case series of severe SMCHD1-related disease have noted male predominance — this claim requires primary-source verification before curation, and should not be asserted without a direct citation).

10. Diagnostics

Genetic testing algorithm (per 2024 international best-practice guidelines)

The definitive reference is: Giardina et al., "Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines," Clinical Genetics 2024 (PMID:38685133; full text):

1. First-tier: D4Z4 repeat-array sizing (Southern blot with EcoRI/EcoRI-BlnI digestion, or molecular combing/optical genome mapping in newer protocols) plus 4qA/4qB haplotyping, to test for the FSHD1 contraction (1–10 repeat units on a permissive 4qA allele).
2. Second-tier, if FSHD1 testing is negative but clinical suspicion remains: D4Z4 methylation analysis (methylation-sensitive restriction digestion at the DR1 region, Southern blot–based) and SMCHD1 gene sequencing (all 18 exons). DNMT3B and LRIF1 sequencing are considered if SMCHD1 is negative.
3. Methylation thresholds: control mean methylation ~45%; FSHD2 mean ~11%, generally <25% by the classic threshold, refined in 2024 to distinct thresholds for 4qA/4qA vs. 4qA/4qB genotypes, with an overall SMCHD1-carrier ceiling of <40% on the DR1 assay. (Clinical Epigenetics 2024)
4. A 2025 method, D4Z4End2End, provides complete genetic and epigenetic architecture of D4Z4 macrosatellites across FSHD, BAMS, and reference cohorts using long-read/optical approaches. (Genome Research 2026)

Clinical criteria / differential diagnosis

No DSM/ICD-style formal diagnostic-criteria set beyond the combination of clinical phenotype (asymmetric facioscapulohumeral weakness pattern) plus confirmatory molecular testing above. Differential diagnosis includes limb-girdle muscular dystrophies, scapuloperoneal myopathies, mitochondrial myopathy, inflammatory myopathies (polymyositis), and Möbius syndrome (for isolated facial weakness in infancy).

Screening

No population-based newborn or carrier screening program for FSHD2 was identified. Cascade/predictive testing in relatives of a confirmed proband (testing both the SMCHD1/DNMT3B/LRIF1 variant and the 4qA haplotype) is standard practice per the 2024 guidelines, given incomplete penetrance and the need to counsel on digenic transmission risk rather than simple autosomal-dominant risk.

11. Outcome/Prognosis

• Life expectancy: Generally normal; FSHD does not typically shorten lifespan.
• Ambulation loss: An estimated ~20% of patients eventually require wheelchair assistance; one large registry reports a 24% six-year risk of wheelchair use.
• Respiratory outcomes: Restrictive respiratory involvement reported in 0–13% across studies, correlating with pelvic-girdle weakness, wheelchair dependence, and kyphoscoliosis; a large US registry reported an ~8% six-year risk of requiring noninvasive ventilatory support; a Dutch estimate puts ~1% of the whole FSHD population on mechanical ventilation. Diaphragm ultrasound involvement correlates with overall disease severity (2025 study, PMC12426622).
• Complications: Retinal Coats-like disease can progress to retinal detachment and vision loss if unrecognized/untreated, particularly in infantile-onset disease — this is a preventable complication via retinal screening and timely laser photocoagulation/anti-VEGF or steroid implant treatment (case report, PMID:40120751).
• Prognostic factors: FSHD2 as an isolated molecular subtype tends to be milder in some reports, but a co-occurring SMCHD1 variant on an FSHD1 background ("FSHD1+2") produces disproportionately severe disease; double SMCHD1 variants and lower D4Z4 methylation levels correlate with greater severity/penetrance.

(Sources: PMC5898965; Medscape; J Neurol 2022 respiratory follow-up)

12. Treatment

There is currently no FDA/EMA-approved disease-modifying therapy for FSHD or FSHD2. Management is entirely supportive; multiple disease-modifying candidates are in active clinical development, targeting the shared DUX4-derepression mechanism (relevant equally to FSHD1 and FSHD2, since both converge on DUX4 toxicity).

Supportive/rehabilitative care

• Physical/occupational therapy: A 2016 home-exercise-therapy trial showed statistically significant functional improvement without evidence of exercise-induced muscle damage. (URMC PT & FSHD resource; NCIT: NCIT:C15302 Physical Therapy)
• Ankle-foot orthoses (AFOs): for foot drop/dorsiflexion weakness, improving gait, balance, energy expenditure. (NCIT device — bind action term NCIT:C15329/Surgical N/A; AFO is a device, see dismech's device-qualifier convention)
• Scapular fixation surgery (scapulodesis/scapulopexy, "scapulothoracic fusion"): individualized for patients with preserved upper-arm (deltoid/rotator cuff) strength; improves shoulder appearance, function, exercise tolerance, and pain; rehab typically begins 7–12 weeks postoperatively. (NCIT:C16186 Orthopedic Surgical Procedure)
• Respiratory support: noninvasive ventilation for restrictive respiratory failure in advanced disease.
• Genetic counseling: essential given digenic transmission complexity (NCIT:C15240).
• Ophthalmologic and audiologic surveillance: periodic retinal screening (especially in severe/infantile presentations) and hearing assessment are recommended given the extramuscular disease burden; treatment of symptomatic Coats-like retinopathy includes laser photocoagulation, intravitreal anti-VEGF, and corticosteroid implants (PMID:40120751).

(Sources: MDA — FSHD Medical Management; StatPearls FSHD Treatment & Management; PM&R KnowledgeNow rehabilitation review)

Investigational disease-modifying therapies

1. Losmapimod (p38α/β MAPK inhibitor) — FAILED Phase 3. Fulcrum Therapeutics' oral small molecule aimed to reduce DUX4 expression by inhibiting p38 MAPK signaling upstream of the DUX4 network. The Phase 3 REACH trial (260 patients, randomized, double-blind, placebo-controlled, 48 weeks) announced topline results on September 12, 2024: the primary endpoint (change in Reachable Workspace, RWS) was not met, and secondary endpoints did not reach nominal significance. Notably, the placebo arm did not show the expected functional decline seen in the earlier Phase 2 ReDUX4 study, complicating interpretation. Fulcrum subsequently suspended the losmapimod FSHD program. (Fulcrum press release, Sept 2024; NeurologyLive coverage; Institut de Myologie)

2. AOC 1020 (Avidity Biosciences) — Antibody-oligonucleotide conjugate, active/promising. An siRNA conjugated to a muscle-targeting antibody (transferrin receptor 1-targeting AOC platform) designed to knock down DUX4 mRNA directly in muscle. In the ongoing Phase 1/2 FORTITUDE trial (~70 adult participants, randomized, placebo-controlled, double-blind), June 2025 interim results reported >50% reduction in DUX4-regulated target gene expression and trends toward functional improvement (strength/function) versus placebo; the company also reports identification of a circulating biomarker that could shorten future time-to-treatment access. (Avidity press release, June 2025; FSHD Society coverage; Avidity FORTITUDE trial materials)

3. Antisense oligonucleotides (ASO) targeting DUX4 mRNA (preclinical/academic). Systemic antisense therapeutics silencing DUX4 have shown efficacy in the ACTA1-MCM;FLExDUX4 mouse model (see §15), improving muscle mass, function, and histopathology, including in diaphragm muscle specifically. (PMC9313434; PMID:35078334)

4. Other mechanistic candidates identified in patent/preclinical literature: DNA-decoy trapping of DUX4 (PMC7701011), CRISPR-based targeting of the DUX4 distal regulatory element (Sci Rep 2021), and morpholino-mediated DUX4 knockdown (PMID:27378237).

Important therapeutic-note for digenic FSHD2 specifically: because DUX4-directed therapies (ASO/siRNA/AOC) act on the shared downstream effector, they are mechanistically applicable to both FSHD1 and FSHD2 regardless of which upstream digenic combination (D4Z4 contraction vs. SMCHD1/DNMT3B/LRIF1 variant + permissive haplotype) produced the DUX4 derepression — this is a case where the digenic upstream etiology converges on a single actionable node.

13. Prevention

No primary prevention exists for a germline genetic/digenic disease of this kind. Secondary prevention is limited to reproductive genetic counseling (given digenic transmission complexity — risk counseling must separately address the SMCHD1/DNMT3B/LRIF1 variant segregation and the independent 4qA-haplotype segregation) and prenatal/preimplantation genetic testing where requested. Tertiary prevention consists of the surveillance measures noted in §10/12 (retinal and audiologic screening) aimed at preventing avoidable complications (retinal detachment, unrecognized hearing loss) rather than the primary myopathy.

14. Other Species / Natural Disease

No naturally-occurring veterinary or wildlife FSHD2/SMCHD1-mutant disease was identified in this search (unlike, e.g., naturally occurring canine dystrophinopathies). SMCHD1 orthologs exist broadly across mammals (used in the engineered mouse models below); NCBI Gene lists mouse Smchd1 (MGI ortholog) as the basis for laboratory models, but no spontaneous animal SMCHD1-FSHD phenotype was found.

Genotype-adjacent human disease for comparative note: SMCHD1 gain-of-function (ATPase-domain) variants cause Bosma arhinia microphthalmia syndrome (BAMS), a distinct craniofacial malformation syndrome (absent nose, ocular anomalies, hypogonadotropic hypogonadism) with no myopathic component, despite arising from the same gene — an important lump/split distinction to keep separate from FSHD2 in curation, consistent with the CLAUDE.md instruction to keep germline mechanism and downstream phenotype distinct. (PMID:28067909; Nat Genet 2017; Nucleic Acids Research 2023 — shared pathway biology in muscle and neural crest)

15. Model Organisms

Mouse models (the dominant model system for FSHD/DUX4 biology): - ACTA1-MCM;FLExDUX4/+ (a.k.a. "Acta1-MCM;FLExDUX4"): a double-transgenic, tamoxifen-inducible mouse carrying DUX4 exons 1–3 in antisense orientation to the Rosa26 promoter, combined with muscle-specific (ACTA1-driven) tamoxifen-inducible Cre recombinase. This model exhibits chronic, mosaic DUX4 expression even without tamoxifen induction, closely mimicking the low-level, stochastic DUX4 expression pattern of human FSHD muscle, and develops progressive histopathological, molecular, and functional deficits over time. It is described as "the most commonly used [DUX4 mouse model] by academic laboratories." (PMID:39518930 / PMC11545788, 2024; FSHD Society model description) - This model has been used to test systemic antisense oligonucleotide therapeutics targeting DUX4, with chronic treatment suppressing DUX4 mRNA/protein and improving muscle mass, function, and histopathology, including specifically in the diaphragm (PMC9313434; PMID:35078334), and for systemic pharmacotherapeutic treatment more broadly (PMC11241187).

Model characteristics — recapitulation and limitations: The FLExDUX4 mouse models the downstream DUX4-toxicity mechanism shared by both FSHD1 and FSHD2, but does not model the upstream digenic genetics of FSHD2 itself (i.e., it does not carry an SMCHD1 loss-of-function allele or a hypomethylated endogenous D4Z4 array — mice lack a human-equivalent D4Z4/DUX4 macrosatellite locus with the same regulatory architecture). This is an important model-fidelity caveat for FSHD2 curation: any FLExDUX4-mouse evidence supports claims about DUX4-driven muscle toxicity (the convergent downstream mechanism), not claims about SMCHD1-mediated chromatin regulation of D4Z4 specifically. A genuine mouse or other model system carrying an Smchd1 loss-of-function allele exists in the literature for X-inactivation/imprinting biology (SMCHD1's other characterized role), but I did not locate a study in this search explicitly using Smchd1-null mice to model D4Z4/DUX4 derepression or FSHD2 muscle pathology — this should be verified against primary literature before an animal-model claim specific to FSHD2's digenic mechanism is curated.

In vitro / cellular models: Human myoblast/myotube cultures from FSHD2 patient biopsies (used for D4Z4 methylation studies, DUX4-target-gene RNA-seq in trial biomarker work, e.g. Avidity's DUX4 RNA-seq panel) are the standard cellular system; iPSC-derived myogenic models are increasingly used but no FSHD2-specific iPSC paper was retrieved in this search.

Non-mammalian systems: No zebrafish, Drosophila, or C. elegans FSHD2/SMCHD1 disease model was identified in this search (explicitly noted as absent from search results).

Summary of Notable Gaps / Items Requiring Verification Before Curation

Per this repository's attribution and verification standards, the following claims surfaced in this research pass are leads, not verified curated facts, and should be checked against primary sources (PMID full text, direct ontology lookup) before being written into a kb/disorders/ entry:

1. MONDO:0030355 identity — not independently confirmed against a live MONDO release in this session; verify it resolves to the FSHD2/digenic concept before using it as the entry's primary MONDO mapping.
2. HPO term bindings — the facial-weakness and asymmetry terms flagged above were not verified against a live HP lookup; do not bind without running the actual ontology search (per the Ontology Term Contract in CLAUDE.md).
3. Sex ratio — no FSHD2-specific male:female prevalence ratio was located; do not assert one without a direct citation.
4. "FSHD4" naming — no source in this search used "FSHD4" as a disease label; treat this as a naming discrepancy to resolve against the KB's own MONDO snapshot rather than propagate.
5. SMCHD1-null mouse model for D4Z4/DUX4 specifically (as opposed to FLExDUX4's DUX4-transgene approach) was not located and should not be asserted as existing without further search.

Full Source List

• OMIM #158901 — FSHD2, Digenic
• OMIM #158900 — FSHD1
• NORD — FSHD2
• GeneReviews — Facioscapulohumeral Muscular Dystrophy (NBK1443)
• FSHD Society — Genetic Cause
• Lemmers et al. 2012, Nat Genet, PMID:23143600
• Larsen/Sacconi et al., EJHG, PMID:25370034
• Sacconi et al., EJHG (modifier), PMID:24075187
• "Double SMCHD1 variants in FSHD2," EJHG
• "FSHD1 and FSHD2 form a disease continuum," Neurology 2019
• "Differential DNA methylation ... asymptomatic carriers," Neurology
• "Variability of SMCHD1 gene in FSHD patients," Hum Mol Genet / PMC6969370
• "SMCHD1 genetic variants in type 2 FSHD, challenges in predicting pathogenicity," PMC12185756
• "Homozygous nonsense variant in LRIF1," Neurology, PMID:32467356
• "SMCHD1 and LRIF1 converge at D4Z4," Commun Biol
• "Deep characterization of a common D4Z4 variant ... biallelic DUX4 expression," EJHG, PMID:29162933
• "Engineered FSHD mutations ... feedforward DUX4 network activation," 2024, PMC10951985
• "DUX4 Signalling in the Pathogenesis of FSHD," PMC7037115
• Giardina et al. 2024, Clinical Genetics, PMID:38685133 / full text
• "Integrating D4Z4 methylation analysis into clinical practice," Clinical Epigenetics 2024
• "Complete genetic/epigenetic architecture of D4Z4 — D4Z4End2End," Genome Research
• De novo SMCHD1 in BAMS, Nat Genet 2017, PMID:28067909 / PMC6016475
• "FSHD2 and BAMS," Neurology
• SMCHD1 in muscle/neural crest, NAR 2023, full text
• Crystal structure SMCHD1 hinge, Science Signaling 2020, full text
• Genome-wide binding of Smchd1, PNAS 2015, full text
• SMCHD1 ubiquitin-like domain, Commun Biol 2019, PMC8286825
• Deenen et al., population-based incidence/prevalence, Neurology 2014, PMID:25122204
• Dutch FSHD registry cohort profile, NMD 2023
• Journal of Neurology — long-term respiratory follow-up 2022
• PMC5898965 — FSHD overview
• Medscape — FSHD
• EyeWiki — Ophthalmologic Manifestations of FSHD
• Retinopathy case report, PMID:40120751
• Padberg 1995, Muscle & Nerve, retinal vascular disease/hearing loss
• MDA — FSHD Medical Management
• StatPearls — FSHD Treatment & Management
• PM&R KnowledgeNow — Rehabilitation Management
• Fulcrum Therapeutics REACH Phase 3 topline results, Sept 2024, press release / NeurologyLive / Institut de Myologie
• Avidity Biosciences AOC 1020 FORTITUDE trial, press release June 2025 / FSHD Society
• ACTA1-MCM;FLExDUX4 mouse model, 2024, PMID:39518930 / PMC11545788
• Systemic pharmacotherapy in ACTA1-MCM/FLExDUX4 mouse, PMC11241187
• Long-term systemic antisense treatment in FSHD-like mouse, PMC9313434
• Diaphragm antisense therapy in double transgenic mouse, PMID:35078334
• FSHD Society — tunable FSHD-like DUX4 mouse model

Reference Validation

Checked with linkml-reference-validator 0.3.0rc1.

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

• PMID:32467356 (3 mentions) - Identifier did not resolve to a record
• PMID:38685133 (7 mentions) - Identifier did not resolve to a record

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMC:PMC10951985 (abstract only): "feedforward DUX4 network activation,"
• Text part not found as substring: 'feedforward DUX4 network activation,' (note: only abstract available for PMID:38510139, full text may contain this excerpt)

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:31879416 (1 mention) - The Conversional Efficacy of Ex Vivo Lung Perfusion and Clinical Outcomes in Patients Undergoing Transplantation of Donor Lungs by Ex Vivo Lung Perfusion: A Meta-Analysis.
• shared terms: patient

Weighed against this report's own most characteristic terms: fshd2, smchd1, d4z4, disease, variant, fshd1, fshd, dux4, digenic, genetic, molecular, lrif1, dnmt3b, gene, muscle, haplotype, permissive, methylation, mechanism, patient.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0009053 (1 mention) - the report calls it "Scapular winging"; HP calls it Distal lower limb muscle weakness
• HP:0003701 (2 mentions) - the report calls it "Proximal muscle weakness", "Progressive extension from shoulder/face; drives ~20% wheelchair dependence"; HP calls it Proximal muscle weakness
• UBERON:0001630 (1 mention) - the report calls it "skeletal muscle tissue"; UBERON calls it muscle organ
• UBERON:0009471 (1 mention) - the report calls it "orbicularis oculi"; UBERON calls it dorsum of tongue
• UBERON:0003688 (1 mention) - the report calls it "scapular muscle — approximate"; UBERON calls it omentum
• UBERON:0001519 (1 mention) - the report calls it "retina"; UBERON calls it skin of manus
• UBERON:0001846 (1 mention) - the report calls it "cochlea"; UBERON calls it internal ear
• NCIT:C15240 (1 mention) - the report calls it "Genetic counseling: essential given digenic transmission complexity"; NCIT calls it Genetic Counseling**

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0001936 (1 mention) - HP does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0006306 (obsolete DNA methylation) (1 mention)
• GO:0006342 (GO_0006342) (1 mention) - replaced by GO:0031507

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• CL:0000188 (2 mentions) - the report calls it "skeletal muscle fiber/cell"; CL calls it cell of skeletal muscle, and lists "skeletal muscle cell" among its other names
• CL:0000056 (2 mentions) - the report calls it "myoblast, used in vitro"; CL calls it myoblast

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• HP:0003701 - called "Proximal muscle weakness", "Progressive extension from shoulder/face; drives ~20% wheelchair dependence"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.